首页 | 本学科首页   官方微博 | 高级检索  
     

Al18F-NOTA-FAPI-04的自动化合成与体内显像
引用本文:江骁,王潇雄,申太鹏,姚玉唐,李秀丽,谌佳琪,寇莹,陈梅华,陈世容,肖定琼,赵檬,陆皓,李佳屿,胡生焰,胡晓平,罗志福,周星,李川,程祝忠. Al18F-NOTA-FAPI-04的自动化合成与体内显像[J]. 中华核医学与分子影像杂志, 2022, 0(1)
作者姓名:江骁  王潇雄  申太鹏  姚玉唐  李秀丽  谌佳琪  寇莹  陈梅华  陈世容  肖定琼  赵檬  陆皓  李佳屿  胡生焰  胡晓平  罗志福  周星  李川  程祝忠
作者单位:四川省肿瘤医院放射肿瘤学四川省重点实验室;中国原子能科学研究院同位素研究所;北京派特生物技术有限公司;川北医学院影像学院
基金项目:四川省科技计划项目(2019YJ0574)。
摘    要:目的:自动化合成Al18F-1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA)-成纤维细胞激活蛋白抑制剂(FAPI)-04,并进行体内显像,评估其诊断肿瘤的效能。方法:利用All-in-one型自动合成模块合成Al18F-NOTA-FAPI-04,并进行质量分析;取3只正常BALB/c小鼠和3只4T1小鼠乳腺癌荷瘤小鼠进行PET/CT显像,观察体内Al18F-NOTA-FAPI-04分布情况;对1例肝细胞肝癌患者(男,51岁)进行Al18F-NOTA-FAPI-04和18F-FDG PET/CT显像,评估其对肝癌的诊断效能。结果:自动化合成Al18F-NOTA-FAPI-04的时间约为35 min,合成产率约为(25.2±1.9)%(衰减校正后,n=3),产品为无色透明溶液,pH值为7.0~7.5,其比活度为(46.11±3.07)GBq/μmol(衰减校正后,n=3),放化纯大于99.0%,室温放置6 h后放化纯仍大于98.0%。小鼠体内显像示Al18F-NOTA-FAPI-04的生理性摄取主要在胆道系统和膀胱中,且高度浓聚于肿瘤病灶区域;肝细胞肝癌患者PET/CT显像示Al18F-NOTA-FAPI-04和18F-FDG PET/CT在胸骨旁淋巴结、膈上前组淋巴结、肝门区淋巴结、胰十二指肠韧带区淋巴结、腹主动脉旁淋巴结的靶本比值(TBR)分别为4.1、8.9、5.4、4.8、2.2和1.0、2.8、5.0、2.1、1.1。结论:基于All-in-one型自动合成模块合成Al18F-NOTA-FAPI-04,合成时间较短、产率高、稳定性好,高度浓聚于病灶区域,其PET图像对比度高,诊断性能优异。

关 键 词:膜蛋白质类  成纤维细胞  氟放射性同位素  正电子发射断层显像术  体层摄影术,X线计算机  小鼠  拮抗剂和抑制剂

Automatic synthesis and in vivo imaging of Al18F-NOTA-FAPI-04
Jiang Xiao,Wang Xiaoxiong,Shen Taipeng,Yao Yutang,Li Xiuli,Shen Jiaqi,Kou Ying,Chen Meihua,Chen Shirong,Xiao Dingqiong,Zhao Meng,Lu Hao,Li Jiayu,Hu Shengyan,Hu Xiaoping,Luo Zhifu,Zhou Xing,Li Chuan,Cheng Zhuzhong. Automatic synthesis and in vivo imaging of Al18F-NOTA-FAPI-04[J]. Chinese Journal of Nuclear Medicine, 2022, 0(1)
Authors:Jiang Xiao  Wang Xiaoxiong  Shen Taipeng  Yao Yutang  Li Xiuli  Shen Jiaqi  Kou Ying  Chen Meihua  Chen Shirong  Xiao Dingqiong  Zhao Meng  Lu Hao  Li Jiayu  Hu Shengyan  Hu Xiaoping  Luo Zhifu  Zhou Xing  Li Chuan  Cheng Zhuzhong
Affiliation:(Radiation Oncology Key Laboratory of Sichuan Province,Sichuan Cancer Hospital,Chengdu 610041,China;Institute of Isotope,China Institute of Atomic Energy,Beijing 102413,China;Beijing PET Technology Corporation,Beijing 100093,China;North Sichuan Medical College,Nanchong 637000,China)
Abstract:Objective To automatically synthesize Al18F-1,4,7-triazacyclononane-1,4,7-triacetic acid(NOTA)-fibroblast activation protein inhibitor(FAPI)-04,perform PET/CT imaging in vivo,and evaluate its diagnostic efficacy on tumors.Methods Al18F-NOTA-FAPI-04 was produced in All-in-one automatic synthesis module and its quality control was conducted by high performance liquid chromatography(HPLC)equipped with a radioactive detector.Al18F-NOTA-FAPI-04 PET/CT imaging was performed in normal BALB/c mice(n=3)and 4T1 breast cancer models(n=3)to determine its biodistribution.Then Al18F-NOTA-FAPI-04 and18F-FDG PET/CT imaging were performed in a hepatocellular carcinoma patient(male,51 years old).Results The synthesis time of Al18F-NOTA-FAPI-04 was about 35 min,and the radiochemical yield was(25.2±1.9)%(attenuation correction,n=3).The product was colorless transparent solution with pH value of 7.0-7.5,and the specific activity was(46.11±3.07)GBq/μmol(attenuation correction,n=3).The radiochemical purity was above 99.0%and was still above 98.0%at room temperature after 6 h.PET/CT imaging in mice showed that physiological uptake of Al18F-NOTA-FAPI-04 was mainly in biliary system and bladder,and Al18F-NOTA-FAPI-04 highly concentrated in tumor xenografts.PET/CT imaging in the patient showed that Al18F-NOTA-FAPI-04 obtained high tumor background ratio(TBR)values of 4.1,8.9,5.4,4.8,2.2 in parasternal lymph nodes,anterior diaphragmatic lymph nodes,hilar lymph nodes,pancreaticoduodenal ligament lymph nodes,abdominal aortic lymph nodes,respectively,while TBR values were 1.0,2.8,5.0,2.1,1.1 by18F-FDG.Conclusions Al18F-NOTA-FAPI-04 can be synthesized with short time,high radiochemical yield and good stability using All-in-one module.Al18F-NOTA-FAPI-04 PET/CT imaging has high contrast and excellent diagnostic efficacy on tumors.
Keywords:Membrane proteins  Fibroblasts  Fluorine radioisotopes  Positron-emission tomography  Tomography,X-ray computed  Mice  Antagonists and inhibitors
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号